ArticleCurrent oncology (Toronto, Ont.)2017
Ovarian function after chemotherapy in young breast cancer survivors.
Article in Current oncology (Toronto, Ont.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.Human reproduction update · 2022Pooled it
- Computerized programs for cancer survivors with cognitive problems: a systematic review.Journal of cancer survivorship : research and practice · 2019Pooled it
- Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.Current treatment options in oncology · 2026Review
- The Impact of Conventional Chemotherapy Regimens and Targeted Drugs on Ovarian Function in Breast Cancer Patients.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- The roles of anti-Müllerian hormone in breast cancer.Endocrine-related cancer · 2023Review
- The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults-A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Effects of Ovarian Tissue Cryopreservation on Primary Ovarian Insufficiency in Girls Undergoing Bone Marrow Transplantation.Journal of pediatric and adolescent gynecology · 2023Article
- Article
- Protective Effect and Mechanism of Melatonin on Cisplatin-Induced Ovarian Damage in Mice.Journal of clinical medicine · 2022Article
- Reproductive Outcomes in Young Breast Cancer Survivors Treated (15-39) in Ontario, Canada.Current oncology (Toronto, Ont.) · 2022Article
- Clinical characteristics, pregnancy outcomes and ovarian function of pregnancy-associated breast cancer patients: a retrospective age-matched study.BMC cancer · 2022Article
- Bone marrow-derived mesenchymal stem cells combined with gonadotropin therapy restore postnatal oogenesis of chemo-ablated ovaries in rats via enhancing very small embryonic-like stem cells.Stem cell research & therapy · 2021Article
- A review on the relationship between anti-mullerian hormone and fertility in treating young breast cancer patients.BMC women's health · 2021Review
- Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women.Breast cancer (Dove Medical Press) · 2021Review
- Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer.Experimental and therapeutic medicine · 2020Article
- Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments.Journal of ovarian research · 2019Article
- Contraceptive utilization and counseling among breast cancer survivors.Journal of cancer survivorship : research and practice · 2019Article
- What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?Journal of the National Cancer Institute · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs cure rates for breast cancer improve, there is increasing evidence that late effects of treatment-and impaired fertility in particular-are emerging as important concerns among young breast cancer survivors. Older reports have evaluated the occurrence of amenorrhea after treatment, but few data have been reported about the incidence of biochemical evidence for impaired ovarian function in patients who do not become overtly menopausal.
methodsWe conducted a cross-sectional study evaluating anti-Müllerian hormone (amh) in premenopausal chemotherapy-treated breast cancer survivors and control patients. Random serum levels of amh and other relevant clinical data were collected for 100 premenopausal chemotherapy-treated breast cancer survivors and 76 control subjects. Subgroup analyses were performed for women with regular menstrual cycles at the time of amh testing.
resultsAfter adjustment for age, amh was significantly lower in the overall group of patients receiving chemotherapy (
conclusionsYoung breast cancer survivors often experience significant impairment of ovarian function despite having normal menstrual cycles after treatment. Those results have important implications for patient counselling and the timing of possible referral to a fertility specialist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.